After confirming the nanomolar-potency of VT107 in the Hippo-pathway mutant mesothelioma cell lines NCI-H2052 (NF2, LATS2 mutant) and NCI-H226 (NF2−/−) (Miyanaga et al, 2015; Murakami et al, 2011; Sekido et al, 1995) (Fig. 1A,B), we used immunoblotting, RNA sequencing (RNA-seq) and proteomics analyses to validate its on-target activity (Figs. 1C–H and EV1, Datasets EV1 and EV2). This evidence concerns the gene LATS2 and mesothelioma.